Xu, J., Cui, Y., Zhang, L., Wang, S., Pan, Z., Jiang, Z. (2026). Firmonertinib combined with cisplatin/carboplatin plus pemetrexed as neoadjuvant therapy in resectable stage II-IIIb
                    <i>EGFR</i>
                    -mutated non–small cell lung cancer: A single-arm, single-center, open-label phase II study.. Journal of Clinical Oncology. https://doi.org/10.1200/jco.2026.44.16_suppl.8058